ah-23848 and Shock--Septic

Despite numerous suggestions in the literature that thromboxane A2 is involved in a variety of occlusive vascular diseases, no definitive evidence is available. Arguments have been presented to support the view that such evidence can only come from clinical studies with a highly specific thromboxane receptor-blocking drug. We have now identified such a drug, AH23848, in our laboratories. Preliminary experiments with AH23848, ([1 alpha (Z), 2 beta,5 alpha]-(+/-)-7-[5-[[(1,1'-biphenyl)-4-yl]methoxy]-2-(4-morpholin yl)-3-oxocyclopentyl]-4-heptenoic acid), show that it is a potent, specific thromboxane receptor-blocking drug that is orally active and has a long duration of action. It should be a valuable tool in elucidating any physiologic or pathologic role of thromboxane A2.

Topics: Angina Pectoris; Animals; Biphenyl Compounds; Collagen; Dogs; Dose-Response Relationship, Drug; Guinea Pigs; Humans; In Vitro Techniques; Male; Muscle, Smooth, Vascular; Platelet Aggregation; Rats; Receptors, Cell Surface; Receptors, Prostaglandin; Receptors, Thromboxane; Shock, Septic; Thromboxane A2; Thromboxane-A Synthase; Vasoconstriction